
The Centers for Medicare & Medicaid Services (CMS) has finalized this rule, which will test whether using international drug prices to calculate manufacturer rebates for certain high-cost Medicare Part B drugs can reduce costs for beneficiaries and Medicare while preserving or improving quality of care.
Drug manufacturers included in the model will be required to participate and may owe rebates to Medicare when U.S. drug prices are higher than prices in economically comparable countries. The model will operate in randomly selected geographic areas, and beginning April 1, 2027, eligible beneficiaries in those areas may pay lower coinsurance when they receive a GLOBE drug. Health care providers are not model participants and will continue to buy, bill, and receive payment for these drugs as usual; when beneficiary coinsurance is reduced, Medicare will increase its share of the payment so that the Medicare allowed amount does not decrease.
For drugs purchased through the 340B Drug Pricing Program, CMS will exclude 340B billing units when calculating manufacturer rebates under GLOBE and will monitor the model’s potential effects on 340B drug prices. The model begins January 1, 2027; CMS will publish the selected geographic areas by ZIP Code by January 16, 2027; and the five performance years will run from April 1, 2027, through March 31, 2032.